The effectiveness of buprenorphine-naloxone on opioid use disorder
| dc.contributor.advisor | Offrey, Laura | |
| dc.contributor.author | McDermott, Emily | |
| dc.date.accessioned | 2025-02-13T16:44:45Z | |
| dc.date.available | 2025-02-13T16:44:45Z | |
| dc.date.issued | 2022 | |
| dc.description | This work was submitted for an assignment in PSYC 399 on November 28, 2022 at MacEwan University located in Edmonton, Alberta. | |
| dc.description.abstract | Opioid use disorder (OUD) is a disorder characterized by extreme opioid misuse which causes issues within all aspects of life. To treat OUD, buprenorphine-naloxone (BNX) is used as a partial opioid agonist paired with naloxone to discourage injection. This medication is often prescribed as a sublingual medication for participants to self-administer. This paper investigates the effectiveness of BNX on treating OUD by examining various empirical studies concerning BNX. The studies suggest BNX has a moderate to strong effectiveness on treating OUD compared to other available treatments. Future directions primarily consist of addressing the common limitation of low retention rates in treatment through a variety of means. Assessment of BNX on OUD is necessary as the opioid crisis present in North America continues to grow. | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14078/3817 | |
| dc.language.iso | en | |
| dc.rights | All Rights Reserved | |
| dc.subject | opioid use disorder | |
| dc.subject | buprenorphine-naloxone | |
| dc.subject | opioid replacement therapy | |
| dc.title | The effectiveness of buprenorphine-naloxone on opioid use disorder | en |
| dc.type | Student Report |
Files
Original bundle
1 - 1 of 1